Incyte
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate INCA033989 Administered in Participants With Myeloproliferative Neoplasms
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 140
- Registration Number
- NCT06034002
- Locations
- ๐บ๐ธ
City of Hope Medical Center, Duarte, California, United States
๐บ๐ธStanford Cancer Institute, Palo Alto, California, United States
๐บ๐ธUniversity of Miami Health System, Miami, Florida, United States
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 5
- Registration Number
- NCT05949632
- Locations
- ๐ฌ๐ง
Beatson West of Scotland Cancer Centrewester, Glasgow, United Kingdom
๐ฌ๐งAddenbrookes Hospital, Cambridge, United Kingdom
๐ฌ๐งSt Bartholomew'S Hospital, London, United Kingdom
Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria
- Conditions
- UrticariaHivesAngioedemaPruritisChronic Spontaneous UrticariaChronic Idiopathic Urticaria
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-04-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 136
- Registration Number
- NCT05936567
- Locations
- ๐บ๐ธ
Clinical Research Center of Alabama, Birmingham, Alabama, United States
๐บ๐ธCahaba Dermatology, Birmingham, Alabama, United States
๐บ๐ธFoothills Research Center, Scottsdale, Arizona, United States
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- Conditions
- Myeloproliferative Neoplasms
- Interventions
- First Posted Date
- 2023-07-07
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 225
- Registration Number
- NCT05936359
- Locations
- ๐ฆ๐บ
Royal Brisbane and Women'S Hospital, Herston, Queensland, Australia
๐ฆ๐บRoyal Adelaide Hospital, Adelaide, South Australia, Australia
๐ฆ๐บPeter Maccallum Cancer Centre, Melbourne, Victoria, Australia
Observational Study for Patients at Risk for Chronic Graft-Versus-Host Disease
- Conditions
- cGVHD
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2023-06-26
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 1500
- Registration Number
- NCT05919511
- Locations
- ๐บ๐ธ
Mayo Clinic Arizona, Phoenix, Arizona, United States
๐บ๐ธMayo Clinic Jacksonville, Jacksonville, Florida, United States
๐บ๐ธMayo Clinic Rochester, Rochester, Minnesota, United States
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-01-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 186
- Registration Number
- NCT05906628
- Locations
- ๐บ๐ธ
First Oc Dermatology, Fountain Valley, California, United States
๐บ๐ธSkin Research of South Florida, Llc, Miami, Florida, United States
๐บ๐ธDermatology Clinical Research Center of San Antonio, San Antonio, Texas, United States
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
- Conditions
- MelanomaColorectal Carcinoma (CRC)Hepatocellular Carcinoma (HCC)Renal Cell Carcinoma (RCC)Microsatellite Instability - High (MSI-H)Mismatch Repair Deficient (dMMR)
- Interventions
- Drug: INCB 99280 with Ipilimumab
- First Posted Date
- 2023-06-18
- Last Posted Date
- 2025-02-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 8
- Registration Number
- NCT05909995
- Locations
- ๐ฟ๐ฆ
Johese Clinical Research: Midstream, Centurion, South Africa
๐จ๐ฆPrincess Margaret Cancer Center, Toronto, Ontario, Canada
๐ฟ๐ฆMary Potter Oncology Centre, Pretoria, South Africa
A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma
- Conditions
- Cutaneous Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2023-06-05
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 63
- Registration Number
- NCT05888844
- Locations
- ๐ซ๐ท
Hopital Charles Nicolle Chu Rouen Hospital de Bois-Guillaume, Rouen Cedex, France
๐ซ๐ทCentre Hospitalier de Pau - Hรดpital Franรงois Mitterrand, Pau Cedex, France
๐ซ๐ทUniversity Hospital of Saint Etienne, Saint Etienne Cedex 2, France
A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 73
- Registration Number
- NCT05879822
- Locations
- ๐ง๐ท
Fundacao Pio Xii Hospital de Cancer de Barretos, Barretos, Brazil
๐ง๐ทCionc-Centro Integrado de Oncologia de Curitiba, Curitiba, Brazil
๐ง๐ทOncosite - Centro de Pesquisa Clinica E Oncologia, Ijui, Brazil
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma
- Conditions
- Moderate to Severe Asthma
- Interventions
- First Posted Date
- 2023-05-09
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 240
- Registration Number
- NCT05851443
- Locations
- ๐ฆ๐ท
Centro Medico Dharma, Mendoza, Argentina
๐ฏ๐ตIdaimae Minami Yojo Int Clinic, Sapporo, Japan
๐ฏ๐ตTokyo Shinagawa Hospital, Shinagawa-ku, Japan